share_log

NexImmune | 8-K: Current report

NexImmune | 8-K: Current report

NexImmune | 8-K：重大事件
美股SEC公告 ·  08/28 04:06
牛牛AI助理已提取核心訊息
NexImmune, Inc. has announced significant changes to its corporate structure following the approval of the company's liquidation and dissolution by stockholders on August 9, 2024. On August 21, 2024, the entire Board of Directors, including Sol J. Barer, Kristi Jones, Alan S. Roemer, Tim Bertram, Paul D’Angio, Grant Verstandig, Zhengbin (Bing) Yao, and Leena Gandhi, tendered their resignations effective August 27, 2024. Additionally, key executive officers, including CEO Kristi Jones, CSO Mathias Oelke, and Interim CFO Albert N. Marchio II, also resigned effective the same date. These resignations were not due to any disagreements with the company's operations, policies, or practices. Concurrently, Craig Jalbert was appointed as the President, Treasurer, Corporate Secretary, and the sole member of the Board, effective August 27, 2024. Jalbert, with...Show More
NexImmune, Inc. has announced significant changes to its corporate structure following the approval of the company's liquidation and dissolution by stockholders on August 9, 2024. On August 21, 2024, the entire Board of Directors, including Sol J. Barer, Kristi Jones, Alan S. Roemer, Tim Bertram, Paul D’Angio, Grant Verstandig, Zhengbin (Bing) Yao, and Leena Gandhi, tendered their resignations effective August 27, 2024. Additionally, key executive officers, including CEO Kristi Jones, CSO Mathias Oelke, and Interim CFO Albert N. Marchio II, also resigned effective the same date. These resignations were not due to any disagreements with the company's operations, policies, or practices. Concurrently, Craig Jalbert was appointed as the President, Treasurer, Corporate Secretary, and the sole member of the Board, effective August 27, 2024. Jalbert, with over 30 years of experience in handling distressed businesses, will oversee the company's wind-down process and will be compensated $50,000 annually for three years. The Board has also approved the filing of a certificate of dissolution with the Secretary of State of Delaware, marking the commencement of the company's dissolution process. NexImmune cautions that trading in the company's securities is highly speculative and poses substantial risks, advising extreme caution for current and potential investors.
NexImmune公司在2024年8月9日獲得股東批准公司清算和解散後，宣佈了對其公司架構的重大變化。2024年8月21日，董事會的所有成員，包括Sol J. Barer、Kristi Jones、Alan S. Roemer、tim Bertram、Paul D’Angio、Grant Verstandig、Zhengbin（Bing）Yao和Leena Gandhi，自願於2024年8月27日生效遞交了辭職信。此外，包括CEO Kristi Jones、CSO Mathias Oelke和臨時CFO Albert N. Marchio II在內的關鍵高管也於同一日期生效辭職。這些辭職並非因...展開全部
NexImmune公司在2024年8月9日獲得股東批准公司清算和解散後，宣佈了對其公司架構的重大變化。2024年8月21日，董事會的所有成員，包括Sol J. Barer、Kristi Jones、Alan S. Roemer、tim Bertram、Paul D’Angio、Grant Verstandig、Zhengbin（Bing）Yao和Leena Gandhi，自願於2024年8月27日生效遞交了辭職信。此外，包括CEO Kristi Jones、CSO Mathias Oelke和臨時CFO Albert N. Marchio II在內的關鍵高管也於同一日期生效辭職。這些辭職並非因與公司運營、政策或實踐存在分歧。與此同時，Craig Jalbert被任命爲總裁、財務主管、公司秘書和董事會的唯一成員，於2024年8月27日生效。擁有超過30年處理財務困境企業經驗的Jalbert將監督公司的清算過程，並將每年獲得5萬美元的報酬，爲期三年。董事會還批准了向特拉華州州務卿提交清算證書的申請，標誌着公司解散程序的開始。NexImmune提醒稱，公司證券的交易具有極大風險，建議現有和潛在投資者極度謹慎。

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。